Eric Adams
Chief Executive Officer presso INMED PHARMACEUTICALS INC.
Patrimonio netto: 16 001 $ in data 31/03/2024
Profilo
Eric A.
Adams is the President, Chief Executive Officer & Director of InMed Pharmaceuticals, Inc. He was the Chief Executive Officer of Ronin8 Technologies Ltd.
from 2014 to 2015.
He was the Director-Oncology Marketing at QLT, Inc. from 1998 to 2002.
He was a Non-Executive Director at enGene, Inc. from 2011 to 2013.
He was the Senior Manager-Business Development at Abbott Laboratories from 1992 to 1996.
He was the Country Manager at Fresenius SE & Co. KGaA from 1988 to 1992.
Mr. Adams has a graduate degree from the University of South Carolina and an undergraduate degree from the University of Southern Indiana.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 20/02/2024 | 43 959 ( 0.73% ) | 16 001 $ | 31/03/2024 |
Posizioni attive di Eric Adams
| Società | Posizione | Inizio |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Chief Executive Officer | 16/06/2016 |
Precedenti posizioni note di Eric Adams
| Società | Posizione | Fine |
|---|---|---|
Ronin8 Technologies Ltd.
 Ronin8 Technologies Ltd. Environmental ServicesIndustrial Services Ronin8 Technologies Ltd. provides materials recovery facilities. It captures the metals in electronic waste without destroying the non-metals. The company was founded by Bruce Sifton and Peter Holgate in 2015 and is headquartered in Vancouver, Canada. | Chief Executive Officer | 01/02/2015 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Executive Officer | 01/07/2013 |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Sales & Marketing | 01/12/2002 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/08/1996 |
| FRESENIUS SE & CO. KGAA | Corporate Officer/Principal | 01/06/1992 |
Formazione di Eric Adams
| University of South Carolina | Graduate Degree |
| University of Southern Indiana | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| FRESENIUS SE & CO. KGAA | Health Technology |
| INMED PHARMACEUTICALS INC. | Health Technology |
| Aziende private | 3 |
|---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
Ronin8 Technologies Ltd.
Ronin8 Technologies Ltd. Environmental ServicesIndustrial Services Ronin8 Technologies Ltd. provides materials recovery facilities. It captures the metals in electronic waste without destroying the non-metals. The company was founded by Bruce Sifton and Peter Holgate in 2015 and is headquartered in Vancouver, Canada. | Industrial Services |
- Borsa valori
- Insiders
- Eric Adams
